Mutant IDH-1 Inhibitor Selectivity for 2-HG Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for therapeutic compounds that selectively inhibit the production of 2-HG from cancer cells harboring IDH-1 mutations, particularly R132S, R132G, and R132L, while remaining inactive at wild type IDH-1 cells and mIDH-2 cells, to treat cancers such as hematological malignancies and solid tumors.
Innovation Solution
Compound 1, a small molecule inhibitor, targets mutant IDH-1 variants R132L, R132G, and R132S, inhibiting 2-HG production with clinically relevant potency and remaining inactive at wild-type IDH-1 and mIDH-2 enzymes, administered at 150 mg orally twice daily for at least 6 months.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a small molecule inhibitor is designed to target mutant IDH-1 variants (R132L, R132G, R132S), then selective inhibition of 2-HG production is achieved, but the inhibitor may inadvertently affect wild-type IDH-1 or mIDH-2 enzymes
Solution Approach 1:
The inhibitor is designed with specific molecular features that create local chemical interactions tailored to the unique structure of mutant IDH-1 variants at position R132. The compound exhibits different binding affinities and inhibitory potencies for different mutant variants (R132L, R132G, R132S) compared to wild-type IDH-1 or mIDH-2, achieving selective inhibition through localized structural recognition.
Solution Approach 2:
The inhibitor's binding characteristics and inhibitory parameters are optimized to specifically recognize and bind to mutant IDH-1 variants. The compound demonstrates distinct IC50 values and binding affinities for different mutant variants, with selective inhibition achieved through parameter differentiation between mutant and wild-type enzymes.
2Reliability
If the inhibitor is administered at high doses to ensure potent inhibition of 2-HG production, then cancer cell metabolism is effectively targeted, but toxicity and side effects increase
Solution Approach 1:
The inhibitor achieves potent inhibition at clinically relevant concentrations through optimized binding parameters and selective affinity for mutant IDH-1 variants. The compound's pharmacological parameters are tuned to provide effective 2-HG suppression at doses that minimize toxicity, achieving a favorable therapeutic index.
3Ease of operation
If the inhibitor is designed to be orally bioavailable and stable, then ease of administration is improved, but the compound may undergo metabolic degradation before reaching the target
Solution Approach 1:
The inhibitor is designed as a composite molecular structure combining pharmacological activity with metabolic stability features. The compound incorporates structural elements that provide both oral bioavailability and resistance to metabolic degradation, achieving a balanced pharmacokinetic profile suitable for chronic cancer therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Compound 1 effectively reduces 2-HG levels by >90% in cancer cells, demonstrating selective inhibition of IDH-1 mutations, including R132L and R132S, with minimal impact on wild-type IDH-1 and mIDH-2, showing clinical efficacy in treating cancers like AML and MDS.
Implementation Method 1
Compound 1 is a small molecule inhibitor of mutated forms of isocitrate dehydrogenase 1 (IDH-1) enzyme... effectively reduces 2-HG levels by >90% in cancer cells, demonstrating selective inhibition of IDH-1 mutations
Data Source
AI summary
Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.